Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OGT 918: Phase I/II

OGS published in The Lancet results of its 1-year, 28-patient international Phase I/II open

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE